Hovione has named Mike Ironside as General Manager of its Technology Transfer Center (TTC), which is located in New Jersey. Ironside was most recently with Anacor Pharmaceuticals and has previously worked for GSK and AMRI.
Hovione VP of Corporate R&D Thomas Eisele said, “This is a key appointment at an important time for Hovione. We are certain that Dr. Ironside’s leadership qualities combined with his relevant experience in chemical and analytical process development, scale-up from pilot plant to full commercial scale will enable us to further strengthen and enlarge our US operations in New Jersey and add new approaches to solve our customers’ most challenging problems.”
“I am excited and honoured about this new opportunity to lead the Hovione team in New Jersey. Throughout my career I have had a great respect for Hovione, a company that is recognized as world leader in pharmaceutical manufacture and particle design. I am looking forward to helping further enhance the TTC’s established reputation for offering our customers integrated solutions for any molecule,” Ironside responded.
Last week, Hovione announced the appointment of Conrad Winters as Director, Drug Product Development.
Read the Hovione press release.
